Hybridoma cell lines (my-C-CC0C2-235-3H8) and use thereof for producing a monoclonal antibody against the human cardiac myosin binding protein C (C-protein, MYBPC3, CMYBP-C or MY-C)

US9975961B2 · kind B2 · utility

Assignee

• MARTIN-LUTHER-UNIVERSITÄT HALLE-WITTENBERG · DE

Inventors

• Ekkehard Weber · Essen, DE
• Rita Medek · Bodenwerder, DE

Key dates

• Filing date: Jan 23, 2015
• Grant date: May 22, 2018
• Expiry date: Jan 23, 2035

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/34
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

Monoclonal antibodies, which can be produced in vitro, against cardiac epitopes of the human My-C are produced by generating myeloma cell clones that produce such specific antibodies having epitope specificity. These monoclonal antibodies allow, among other things, the creation of an enzyme-linked immunosorbent assay (ELISA) for the specific, cross-reactivity-free quantitative determination of My-C in serum, plasma, whole blood or other body fluid. Specifically, a hybridoma cell clone producing a monoclonal antibody that detects and binds a cardiac epitope in the My-C is produced, which has no cross-reactivity with respect to the myosin-binding proteins of the skeletal muscles. The hybridoma cell line can be obtained by fusing myeloma cells with spleen cells of a test animal, in particular a mouse, immunized against recombinant My-C.